2-(3-Cumyl)thiazol | 42156-19-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-Cumyl)thiazol
• 英文别名: 2-(3-isopropyl-phenyl)-thiazole；2-(3-Propan-2-ylphenyl)-1,3-thiazole
• CAS: 42156-19-4
• 化学式: C₁₂H₁₃NS
• 分子量: 203.308
• InChiKey: PHPCPCHQEQHELD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  异丙苯 、 2-肼基-1,3-噻唑 在 silver(II) oxide 作用下， 生成 2-(4-isopropylphenyl)thiazole 、 2-(3-Cumyl)thiazol 、 2-(2-Cumyl)thiazol
  参考文献：
  名称：

  Radicals derived from heteroaromatic systems. II. Thiazolyl radicals

  摘要：

  2-噻唑基肼和所有三种噻唑羰基过氧化物已经合成并在苯、溴苯和叔丁基溶液中作为自由基前体进行了检验。银氧化物氧化肼或2-过氧化物的热分解可得到良好的2-芳基噻唑产率，但酯的产量微乎其微；在叔丁基中形成微量的双叔丁基。溴苯和叔丁基中的异构物比例完全支持2-噻唑基自由基的参与。4-羰基过氧化物在苯中产率较高的4-芳基噻唑，但苯基酯也是主要产物，表明了4-噻唑基自由基和噻唑-4-羰基氧自由基的反应。5-过氧化物没有产生明显的5-噻唑自由基或噻唑-5-羰基氧自由基的产物。在叔丁基中，4-和5-过氧化物的反应产生双叔丁基。

  DOI：

  10.1139/v70-595

文献信息

• Modified amino acids, pharmaceuticals containing these compounds and method for their production
  申请人：RUDOLF Klaus

  公开号：US20090163480A1

  公开（公告）日：2009-06-25

  The present invention relates to modified amino acids of general formula wherein A, Z, X, n, m, R, R 2 , R 3 , R 4 and R 11 are defined as in claims 1 to 5 , their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

  本发明涉及一般式为的改性氨基酸，其中A，Z，X，n，m，R，R2，R3，R4和R11如权利要求1至5所定义，它们的互变异构体，对映异构体，混合物及其盐，特别是与无机或有机酸或碱的生理上可接受的盐，含有这些化合物的制药组合物，它们的用途和制备它们的过程，以及它们用于生产和纯化抗体，并用作RIA和ELISA测定中的标记化合物以及神经递质研究中的诊断或分析辅助工具。
• [EN] ANTI-VIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：INFEX THERAPEUTICS LTD

  公开号：WO2022189810A1

  公开（公告）日：2022-09-15

  This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.

  本发明涉及可用于治疗病毒感染的化合物。这些化合物是木瓜蛋白酶类似物酶（PLpro）抑制剂。
• Diazepane derivatives and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10308653B2

  公开（公告）日：2019-06-04

  The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, neurological diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.

  本公开提供了式（I）化合物及其药用组合物。已发现式（I）化合物可结合溴基链和/或含溴基链的蛋白质（如溴外末端（BET）蛋白质）。还提供了这些化合物和药物组合物的方法、用途和试剂盒，用于抑制溴基团和/或含溴基团蛋白的活性（如活性增加），治疗和/或预防受试者与溴基团或含溴基团蛋白相关的疾病（如增殖性疾病、心血管疾病、病毒感染、纤维化疾病、神经系统疾病、代谢性疾病、内分泌疾病和辐射中毒）。这些化合物、药物组合物和试剂盒还可用于男性避孕。
• Combination therapy of transcription inhibitors and kinase inhibitors
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10702527B2

  公开（公告）日：2020-07-07

  The present disclosure provides combination therapy of a transcription inhibitor and a kinase inhibitor. The combination of the transcription inhibitor and the kinase inhibitor may be useful in treating and/or preventing in a subject a proliferative disease, such as proliferative a disease that is resistant to the transcription inhibitor alone or the kinase inhibitor alone. In certain embodiments, the proliferative disease is a cancer. The combination of the transcription inhibitor and the kinase inhibitor is expected to be synergistic.

  本公开提供了转录抑制剂和激酶抑制剂的组合疗法。转录抑制剂和激酶抑制剂的组合可用于治疗和/或预防受试者的增殖性疾病，如对单独转录抑制剂或单独激酶抑制剂耐药的增殖性疾病。在某些实施方案中，增殖性疾病是癌症。转录抑制剂和激酶抑制剂的组合可望产生协同作用。
• EZH2 inhibitors and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US11236082B2

  公开（公告）日：2022-02-01

  The present disclosure provides compounds of any one of Formulae (I) and (II). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. Further provided in the present disclosure are methods of identifying EZH1 and/or EZH2 inhibitors.

  本公开提供了式(I)和(II)中任一项的化合物。本文所述化合物是组蛋白甲基转移酶（如泽斯特同源增强子 1 (EZH1)和泽斯特同源增强子 2 (EZH2)）的抑制剂，可用于治疗和/或预防多种疾病（如增殖性疾病）。本公开还提供了包括或使用本文所述化合物的药物组合物、试剂盒、方法和用途。本公开还提供了鉴定EZH1和/或EZH2抑制剂的方法。